Overview

Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Status:
Completed

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.

Phase:

Phase 3

Details

Lead Sponsor:

Sunovion

Treatments:

Anticonvulsants
Eslicarbazepine acetate